Hunter-Fleming Ltd Report issue

For profit Phase 2
Founded: Bristol United Kingdom (1999)
Status: Acquired by Newron Pharmaceuticals (2008)

Organization Overview

First Clinical Trial
2006
NCT00357357
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

7-beta-Hydroxyepiandrosterone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1